Axsome Therapeutics AXSM Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Milestone Revenue | $500K— | —— | —— | —— | —— | |
| Royalty And Milestone Revenue | $1.8M— | —— | —— | —— | $1.11M+10.1% | |
| Royalty | $4.07M— | —— | $2.07M+91.2% | $1.08M-2.0% | $1.11M+121% | |
| Research And Development Expense by Product | ||||||
| Balipodect | $10.4M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Axsome Therapeutics break its business down?
- Axsome Therapeutics (AXSM) reports revenue by product across 3 parts — Milestone Revenue, Royalty And Milestone Revenue and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Axsome Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Axsome Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
